APOC3 and familial hypercholesterolemia: In this pediatric cohort, the evidence for the beneficial effects of APOC3 minor variants on the risk of hypercholesterolemia was limited to an early period after initiation of PI treatment boosted with RTV, and was not verifiable six months later.